BIO Wrap: Biosecure, Japan & Nxera, radiopharma — a BioCentury podcast

What the latest twist for anti-China legislation means. CEO Chris Cargill on Japan and what’s next for Nxera. And radiopharma innovation debates at BIO

The 2024 edition of BIO’s annual meeting took place amid heightened industry concerns regarding the Biosecure Act, which took yet another unexpected turn this week.

On a special edition of the BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses why the U.S. House of Representatives’ decision to leave Biosecure out of a defense spending bill matters, misperceptions of what the bill seeks to accomplish, and the key differences between the House and Senate versions of legislation seeking to rein in Chinese CDMOs and genomics companies in the U.S.

Special guest Chris Cargill, the CEO of Nxera Pharma Co. Ltd. (Tokyo:4565), joins the podcast to discuss the expanded APAC presence at this year’s BIO, in particular by the delegations from South Korea and Japan; the Japanese government’s push to build the biotech ecosystem in the country; and how Nxera (formerly Sosei Group Corp.) is evolving. 

And finally, BioCentury’s Karen Tkach Tuzman delivers the takeaways from her BIO panel focused on radiopharmaceuticals, including lively debate on the merits of long- versus short-lived radioisotopes.

This week’s podcast is sponsored by Nxera Pharma.